|A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #|
Quad ScreenTest Code
82105, 82677, 84702, 86336<br /> **This test is not available for New York state patient testing. For New York State patient testing, use code 16333.**
3 mL serum
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Gross lipemia
Maternal age confirmation and number of fetuses may alter result interpretation. Maternal screening tests consistent with increased risk of trisomy should be confirmed with CVS or amniotic fluid specimen. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.
See Laboratory Report
The use of an additional marker, Dimeric Inhibin A, along with the Maternal Screen 1 tests and maternal age has been found to improve the detection rate with no significant change to the false positive rate. Inhibin A is elevated in the serum of women carrying a Down syndrome fetus. By adding this marker the detection rate improves to 67 - 74%, with a false positive rate of approximately 5%.
The Maternal Serum Screen in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Maternal Serum Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome, or trisomy 18. The "Maternal Serum Screen Requisition" designed to obtain patient data and the patient's informed consent must be used when ordering the Maternal Serum Screen test. Because the Maternal Serum Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: Date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin-dependent before pregnancy), number of fetuses, and whether this is a repeat sample.
|Quest Diagnostics Nichols Institute|
|14225 Newbrook Drive|
|Chantilly, VA 20153|